Enhancing the Understanding of Resilience in Health Systems of Low- and Middle-Income Countries: A Qualitative Evidence Synthesis

by
A nation’s well being system faces stress when hit by an surprising shock, comparable to what we observe in the midst of the coronavirus illness 2019 (COVID-19) pandemic. The idea of resilience is very related in this context and is a prerequisite for a well being system succesful of withstanding future shocks. By exploring how the key dimensions of the resilient well being system framework are utilized, the current systematic evaluate synthesizes the important options of resilient well being methods in low- and middle-income international locations. The goal of this evaluate is to establish the relevance of well being system resilience in the context of a significant shock, via higher understanding its dimensions, makes use of and implications.
The evaluate makes use of the best-fit framework synthesis method. An a priori conceptual framework was chosen and a coding framework created. A systematic search recognized 4284 distinctive citations from digital databases and stories by non-governmental organisations, 12 of which met the inclusion standards. Data had been extracted and coded in opposition to the pre-existing themes. Themes outdoors of the a priori framework had been collated to type a refined listing of themes. Then, all twelve research had been revisited utilizing the new listing of themes in the context of every research.

Ten themes had been generated from the evaluation. Five confirmed the a priori conceptual framework that seize the dynamic attributes of a resilient system. Five new themes had been recognized as foundational for attaining resilience: realigned relationships, foresight and motivation as drivers, and emergency preparedness and change administration as organisational mechanisms. The refined conceptual mannequin exhibits how the themes inter-connect. The foundations of resilience seem like crucial particularly in resource-constrained settings to unlock the dynamic attributes of resilience. This evaluate prompts international locations to think about constructing the foundations of resilience described right here as a precedence to raised put together for future shocks.

Development of a xylosyltransferase-I-selective UPLC MS/MS exercise assay utilizing a selected acceptor peptide

 

Xylosyltransferases-I and -II (XT-I and -II) play an essential position concerning the homeostasis of the extracellular matrix. Both enzymes catalyze the preliminary step of the proteoglycan (PG) biosynthesis by the switch of xylose from their pure substrate uridine diphosphate (UDP) -xylose to a PG-core protein. The subsequent addition of additional sugars, catalyzed by totally different glycosyltransferases, results in the formation of a tetrasaccharide linker, which connects the PG-core protein and glycosaminoglycans. The purpose for the look of two XT isoforms in all greater organisms is just not identified and outstanding, as each enzymes are capable of provoke PG biosynthesis.

The dedication of the XT-I exercise is of medical significance as a result of it may be used as a biomarker of a number of PG-associated fibrotic illnesses. Since earlier assays didn’t adequately differentiate between each XT-isoforms, the goal of this research was to develop an XT-I selective mass spectrometric (MS) assay. For this goal, we initially used isoform-specific supernatants to efficiently determine an artificial acceptor peptide which was xylosylated way more selectively by the XT-I when in comparison with the XT-II isoform.

The assay was additional optimized regarding methodical parameters comparable to the injection quantity and the incubation time of the reaction-mixture. By utilizing samples overlaying a broad XT-activity spectrum, we efficiently validated the assay for use not just for the quantification of cell tradition samples but additionally human serum specimens. Compared to beforehand used XT-activity assays, our newly developed check is extra selective and delicate, inexpensive and simpler to carry out in excessive throughput. Alterations in expression of particular translation components, and disruption of canonical mRNA translational regulation, each contribute to the pathology of many NCDs.

Telehealth Solutions for In-hospital Communication with Patients Under Isolation During COVID-19

 

The coronavirus illness 2019 (COVID-19) pandemic is a public well being disaster that has rapidly overwhelmed our healthcare system. It has led to important shortages in private protecting gear (PPE), ventilators, and intensive care unit beds throughout the nation. As the preliminary entry level for sufferers with suspected COVID sickness, emergency departments (ED) have needed to adapt rapidly to prioritize the security of sufferers and suppliers whereas nonetheless delivering optimum, well timed affected person care. COVID-19 has introduced many challenges for the ED that additionally lengthen to all inpatient companies.

Some of these key challenges are the basic duties of speaking with sufferers in respiratory isolation whereas minimizing PPE utilization and enabling all sufferers who’ve been affected by hospitals’ customer restrictions to join with their households. We talk about the design rules behind implementing a strong in-hospital telehealth system for patient-provider and patient-family communication, present a evaluate of the strengths and weaknesses of potential videoconferencing choices, and ship concise, step-by-step guides for organising a safe, low-cost, user-friendly resolution that may be quickly deployed.

cDNA - Alzheimer's Disease: Brain
C1236035Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Pons
C1236071Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Amygdala
C1236036Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Cerebellum
C1236039Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Hippocampus
C1236052Alz 40 reactions
EUR 975

cDNA - Alzheimer's Disease: Brain: Frontal Lobe
C1236051Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Parietal Lobe
C1236066Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Temporal Lobe
C1236078Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Occipital Lobe
C1236062Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Precentral Gyrus
C1236073Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Postcentral Gyrus
C1236072Alz 40 reactions
EUR 802

Total RNA - Alzheimer's Disease: Brain
R1236035Alz-50 50 ug
EUR 460

Total Protein - Alzheimer's Disease: Brain
P1236035Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Pons
P1236071Alz 1 mg
EUR 542

Frozen Tissue Section - Alzheimer's Disease: Brain
T1236035Alz 5 slides
EUR 523

Total Protein - Alzheimer's Disease: Brain: Amygdala
P1236036Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Cerebellum
P1236039Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Hippocampus
P1236052Alz 1 mg
EUR 667

Total Protein - Alzheimer's Disease: Brain: Frontal Lobe
P1236051Alz 1 mg
EUR 542

Frozen Tissue Section - Alzheimer's Disease: Brain: Pons
T1236071Alz 5 slides
EUR 523

Total Protein - Alzheimer's Disease: Brain: Parietal Lobe
P1236066Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Temporal Lobe
P1236078Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Occipital Lobe
P1236062Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Corpus Callosum
P1236045Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Precentral Gyrus
P1236073Alz 1 mg
EUR 542

Frozen Tissue Section - Alzheimer's Disease: Brain: Amygdala
T1236036Alz 5 slides
EUR 523

Total Protein - Alzheimer's Disease: Brain: Medulla oblongata
P1236057Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Postcentral Gyrus
P1236072Alz 1 mg
EUR 542

Frozen Tissue Section - Alzheimer's Disease: Brain: Pituitary
T1236068Alz 5 slides
EUR 971

Frozen Tissue Section - Alzheimer's Disease: Brain: Cerebellum
T1236039Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Hippocampus
T1236052Alz 5 slides
EUR 971

Paraffin Tissue Section - Alzheimer's Disease: Brain: Cerebellum
T2236039Alz 5 slides
EUR 262

Genomic DNA - Alzheimer's Disease: Brain, from a single donor
D1236035Alz 50 ug
EUR 562

Frozen Tissue Section - Alzheimer's Disease: Brain: Frontal Lobe
T1236051Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Parietal Lobe
T1236066Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Temporal Lobe
T1236078Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Occipital Lobe
T1236062Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Corpus Callosum
T1236045Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Precentral Gyrus
T1236073Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Medulla oblongata
T1236057Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Postcentral Gyrus
T1236072Alz 5 slides
EUR 523

Genomic DNA - Alzheimer's Disease: Brain: Pons, from a single donor
D1236071Alz 50 ug
EUR 562

Paraffin Tissue Section - Alzheimer's Disease: Brain: Medulla oblongata
T2236057Alz 5 slides
EUR 523

Genomic DNA - Alzheimer's Disease: Brain: Cerebellum, from a single donor
D1236039Alz 50 ug
EUR 562

Total Protein - Parkinson's Disease: Brain: Thalamus
P1236079Par 1 mg
EUR 542

Genomic DNA - Alzheimer's Disease: Brain: Frontal Lobe, from a single donor
D1236051Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Parietal Lobe, from a single donor
D1236066Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Temporal Lobe, from a single donor
D1236078Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Occipital Lobe, from a single donor
D1236062Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Corpus Callosum, from a single donor
D1236045Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Precentral Gyrus , from a single donor
D1236073Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Medulla oblongata, from a single donor
D1236057Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Postcentral Gyrus , from a single donor
D1236072Alz 50 ug
EUR 562

Frozen Tissue Section - Parkinson's Disease: Brain: Thalamus
T1236079Par 5 slides
EUR 523

Total Protein - Multiple Sclerosis Disease: Brain: Thalamus
P1236079Msc 1 mg
EUR 542

Paraffin Tissue Section - Parkinson's Disease: Brain: Thalamus
T2236079Par 5 slides
EUR 262

Pons (Alzheimer's Disease) Lysate
XBL-10298 0.1 mg
EUR 796.2
Description: Human pons tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human pons tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the pons tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The pons tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Frozen Tissue Section - Multiple Sclerosis Disease: Brain: Thalamus
T1236079Msc 5 slides
EUR 523

Paraffin Tissue Section - Multiple Sclerosis Disease: Brain: Thalamus
T2236079Msc 5 slides
EUR 262

Amygdala (Alzheimer's Disease) Lysate
XBL-10274 0.1 mg
EUR 796.2
Description: Human amygdala tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human amygdala tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the amygdala tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The amygdala tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Paraffin Tissue Section - Alzheimers Disease: Brain
T2236035Alz 5 slides
EUR 262

Total RNA - Alzheimer's Disease: Pons
R1236071Alz-10 10 ug
EUR 460

Hippocampus (Alzheimer's Disease) Lysate
XBL-10286 0.1 mg
EUR 922.2
Description: Human hippocamps tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human hippocamps tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the hippocamps tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The hippocamps tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Genomic DNA - Parkinson's Disease: Brain: Thalamus, from a single donor
D1236079Par 50 ug
EUR 562

Membrane Protein - Alzheimer's Disease:Brain: Amygdala
P3236036Alz 0.1 mg
EUR 472

Frontal Lobe (Alzheimer's Disease) Lysate
XBL-10282 0.1 mg
EUR 796.2
Description: Human frontal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human frontal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the frontal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The frontal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Paraffin Tissue Section - Alzheimers Disease: Brain: Pons
T2236071Alz 5 slides
EUR 262

Membrane Protein - Alzheimer's Disease:Brain: Hippocampus
P3236052Alz 0.1 mg
EUR 584

Human Alzheimer's Disease Primer Library
HAZD-I 1 set
EUR 657.6

Parietal Lobe (Alzheimer's Disease) Lysate
XBL-10294 0.1 mg
EUR 796.2
Description: Human parietal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human parietal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the parietal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The parietal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Temporal Lobe (Alzheimer's Disease) Lysate
XBL-10314 0.1 mg
EUR 796.2
Description: Human temporal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human temporal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the temporal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The temporal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Occipital lobe (Alzheimer's Disease) Lysate
XBL-10290 0.1 mg
EUR 796.2
Description: Human occipital lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human occipital lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the occipital lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The occipital lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Human iPS Cell Line (Alzheimer's Disease)
CSC-00850L One Frozen vial Ask for price

Corpus Callosum (Alzheimer's Disease) Lysate
XBL-10278 0.1 mg
EUR 796.2
Description: Human corpus Callosum tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human corpus Callosum tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the corpus Callosum tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The corpus Callosum tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Membrane Protein - Alzheimer's Disease:Brain: Temporal Lobe
P3236078Alz 0.1 mg
EUR 472

Precentral Gyrus (Alzheimer's Disease) Lysate
XBL-10306 0.1 mg
EUR 796.2
Description: Human precentral gyrus tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human precentral gyrus tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the precentral gyrus tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The precentral gyrus tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Paraffin Tissue Section - Alzheimers Disease: Brain: Amygdala
T2236036Alz 5 slides
EUR 262

Amygdala (Alzheimer's Disease) Membrane Lysate
XBL-10272 0.1 mg
EUR 752.1
Description: Human brain amygdala tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human amygdala tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain amygdala tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain amygdala tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Postcentral Gyrus (Alzheimer's Disease) Lysate
XBL-10302 0.1 mg
EUR 796.2
Description: Human postcentral gyrus tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human postcentral gyrus tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the postcentral gyrus tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The postcentral gyrus tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Total RNA - Alzheimer's Disease: Frontal Lobe
R1236051Alz-10 10 ug
EUR 460

Genomic DNA - Multiple Sclerosis Disease: Brain: Thalamus, from a single donor
D1236079Msc 50 ug
EUR 562

Total RNA - Alzheimer's Disease: Parietal Lobe
R1236066Alz-10 10 ug
EUR 460

Total RNA - Alzheimer's Disease: Temporal Lobe
R1236078Alz-10 10 ug
EUR 460

Total RNA - Alzheimer's Disease: Occipital Lobe
R1236062Alz-10 10 ug
EUR 460

Hippocampus (Alzheimer's Disease) Membrane Lysate
XBL-10284 0.1 mg
EUR 852.9
Description: Human brain hippocamps tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human hippocamps tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain hippocamps tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain hippocamps tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Paraffin Tissue Section - Alzheimers Disease: Brain: Hippocampus
T2236052Alz 5 slides
EUR 834

Total RNA - Alzheimer's Disease: Corpus Callosum
R1236045Alz-10 10 ug
EUR 460

Paraffin Tissue Section - Alzheimers Disease: Brain: Frontal Lobe
T2236051Alz 5 slides
EUR 262

Total RNA - Alzheimer's Disease: Precentral Gyrus
R1236073Alz-10 10 ug
EUR 460

Paraffin Tissue Section - Alzheimers Disease: Brain: Parietal Lobe
T2236066Alz 5 slides
EUR 262

Paraffin Tissue Section - Alzheimers Disease: Brain: Temporal Lobe
T2236078Alz 5 slides
EUR 262

Total RNA - Alzheimer's Disease: Postcentral Gyrus
R1236072Alz-10 10 ug
EUR 460

Hippocampus (Alzheimer's Disease) Cytoplasmic Lysate
XBL-10283 0.1 mg
EUR 273.3
Description: Human brain hippocamps tissue cytoplasmic protein lysate was prepared by isolating the cytoplasmic protein from whole tissue homogenates using a proprietary technique. The human hippocamps tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The cytoplasmic protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, glycerol, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain hippocamps tissue cytoplasmic protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain hippocamps tissue cytoplasmic protein is then Western analyzed by GAPDH antibody, and the expression level is consistent with each lot.

Paraffin Tissue Section - Alzheimers Disease: Brain: Corpus Callosum
T2236045Alz 5 slides
EUR 262

Paraffin Tissue Section - Alzheimers Disease: Brain: Occipital Lobe
T2236062Alz 5 slides
EUR 262

Temporal Lobe (Alzheimer's Disease) Membrane Lysate
XBL-10312 0.1 mg
EUR 752.1
Description: Human brain temporal lobe tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human temporal lobe tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain temporal lobe tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain temporal lobe tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Non-Ab Component of Alzheimer's Disease Amyloid
5-01639 4 x 1mg Ask for price

Non-Ab Component of Alzheimer's Disease Amyloid
SP-89317-1 1 mg
EUR 343.2

Paraffin Tissue Section - Alzheimers Disease: Brain: Precentral Gyrus (Movement)
T2236073Alz 5 slides
EUR 262

Non-Ab Component of Alzheimer's Disease Amyloid Peptide
abx266991-1ml 1 ml
EUR 925

Non-Ab Component of Alzheimer's Disease Amyloid Peptide
abx266991-200l 200 µl
EUR 375

Paraffin Tissue Section - Alzheimers Disease: Brain: Postcentral Gyrus (Sensation)
T2236072Alz 5 slides
EUR 262

HighQC™ Human IPSC From Fibroblast-Familial Alzheimer's Disease
ABC-SC2075 1 vial Ask for price
Description: Cell Type: iPSC; Primary Tissue: Fibroblast; Reprogramming Method: Episomal Plasmid; Disease: Familial Alzheimer's Disease; Cells are only guaranteed with purchase of Gentaur Media and Gentaur Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Amyloid-beta Protein (12-28) / Alzheimer's Disease beta-Protein / SP-17 (Human)
018-04 200 μg
EUR 50.76

Amyloid-beta Protein (1-28) / Alzheimer's Disease beta-Protein / SP-28 (Human)
018-02 200 μg
EUR 108

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue I, 7 different tissues
T6236444Alz 5 slides
EUR 1249

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue II, 7 different tissues
T6236445Alz 5 slides
EUR 1249

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue III, 8 different tissues
T6236446Alz 5 slides
EUR 1249

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue IV, 7 different tissues
T6236564Alz 5 slides
EUR 1249

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue I, 8 different tissues
T8236444Alz 5 slides
EUR 713

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue II, 7 different tissues
T8236445Alz 5 slides
EUR 713

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue IV, 7 different tissues
T8236564Alz 5 slides
EUR 713

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue III, 8 different tissues
T8236446Alz 5 slides
EUR 713

Alzheimers Disease gamma-Secretase Detection Set
PSI-1820 1 Set
EUR 752.1
Description: Accumulation of the amyloid-β peptide (Aβ) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. The β-amyloid protein precursor (APP) is cleaved by three enzymes (TACE, BACE/BACE2 and γ-secretase) at three distinct sites (α, β and γ respectively). The γ-secretase complex is a membrane-bound aspartyl protease that can cleave certain proteins at peptide bonds buried within the hydrophobic environment of the lipid bilayer and is composed of the proteins APH1, nicastrin, PEN2 and presenilin1. Its cleavage of APP results in either the non-toxic p3 (from the α and γ cleavage site) or the toxic Aβ (from the β and γ cleavage site). APH1 was initially identified as a component of the Notch pathway and exists in at least three distinct isoforms with APH1a as the principal isoform present in the γ-secretase complex. Mice deficient in this isoform, but not the other two, were lethal at E10.5, with impaired vascular and neural development observed. Besides acting as a critical component of the γ-secretase complex, nicastrin is also thought to be involved in cell proliferation and signaling, especially in regards to activation of Notch receptors as loss of nicastrin expression results in mouse embryonic lethality. Presenilin1 was initially identified a marker of susceptibility to early-onset Alzheimer’s disease.;;For images please see PDF data sheet

Alzheimers Disease B-Amyloid Protein Detection Set
PSI-1812 1 Set
EUR 752.1
Description: Accumulation of the amyloid-β peptide (Aβ) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. The βamyloid protein precursor (APP) is cleaved by one of two βsecretases (BACE and BACE2), producing a soluble derivative of the protein and a membrane anchored 99-amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for βsecretase to generate the 4 kDa amyloid-β peptide (Aβ), which is deposited in the Alzheimer’s disease patients’ brains. BACE was identified by several groups independently and designated β-site APP cleaving enzyme (BACE) . BACE is a transmembrane aspartic protease and co-localizes with APP. BACE2 also cleaves APP at β-site and at a different site within Aβ. BACE2 locates on chromosome 21q22.3, the so-called ‘Down critical region’, suggesting that BACE2 and Aβ may also contribute to the pathogenesis of Down syndrome.;;For images please see PDF data sheet

Bovine Brain, Thalamus Frozen Sections
BF-205 10 slides
EUR 261

Total Protein - Dementia: Brain: Thalamus
P1236079Dem 1 mg
EUR 542

Bovine Brain, Thalamus Paraffin Sections
BP-205 10 slides
EUR 240

Total Protein - Depression: Brain: Thalamus
P1236079Dep 1 mg
EUR 542

PSEN2 (untagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1
SC119867 10 µg Ask for price

PSEN2 (untagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2
SC324404 10 µg Ask for price

PSEN2 (untagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2
SC109639 10 µg Ask for price

PSEN2 (GFP-tagged) - Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2
RG202921 10 µg Ask for price

PSEN2 (GFP-tagged) - Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1
RG223613 10 µg Ask for price

Rat Thalamus cDNA
RD-205 30 reactions
EUR 243

PSEN2 (Myc-DDK-tagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1
RC223613 10 µg Ask for price

PSEN2 (Myc-DDK-tagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2
RC202921 10 µg Ask for price

Human Brain Thalamus Lysate Membrane Fraction
IHUBRTHLTLM100UG each
EUR 870
Description: Human Brain Thalamus Lysate Membrane Fraction

Frozen Tissue Section - Dementia: Brain: Thalamus
T1236079Dem 5 slides
EUR 523

Lenti ORF clone of Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, mGFP tagged
RC202921L2 10 µg Ask for price

Lenti ORF clone of Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, mGFP tagged
RC202921L4 10 µg Ask for price

Paraffin Tissue Section - Dementia: Brain: Thalamus
T2236079Dem 5 slides
EUR 262

Non-communicable illnesses (NCDs) are medical circumstances that, by definition, are non-infectious and non-transmissible amongst folks. Much of present NCDs are typically attributable to genetic, behavioral, and metabolic danger components that usually embrace extreme alcohol consumption, smoking, weight problems, and untreated elevated blood stress, and share many frequent sign transduction pathways. Alterations in cell and physiological signaling and transcriptional management pathways have been properly studied in a number of human NCDs, however these identical pathways additionally regulate expression and perform of the protein artificial equipment and mRNA translation which have been much less properly investigated.